Clobazam

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Clobazam is a 1,5-benzodiazepine with established use as a broad-spectrum antiepileptic agent, including FDA-approved adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (ONFI®). The TxGNN model predicts it may be effective for Febrile Infection-Related Epilepsy Syndrome (FIRES), with 0 clinical trials and 2 publications currently supporting this specific direction — making it a mechanistically plausible but clinically uncharted research question.

Quick Overview

Item	Content
Original Indication	Epilepsy (broad-spectrum antiepileptic); FDA-approved for Lennox-Gastaut syndrome seizures (ONFI®)
Predicted New Indication	Febrile Infection-Related Epilepsy Syndrome (FIRES)
TxGNN Prediction Score	99.82%
Evidence Level	L4
Saudi Arabia Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not formally documented in this Evidence Pack. Based on published literature included in the evidence, clobazam belongs to the 1,5-benzodiazepine class — a structural isomer distinct from classical 1,4-benzodiazepines such as diazepam and clonazepam. It acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission to suppress abnormal neuronal firing. Compared to other benzodiazepines, clobazam carries relatively lower sedative and muscle-relaxant liability while maintaining broad-spectrum antiepileptic activity across both focal and generalized seizure types.

FIRES is a catastrophic form of new-onset refractory status epilepticus (NORSE) occurring in previously healthy children. During the acute phase, benzodiazepines are commonly used as first-line agents to achieve seizure control, often escalating to high-dose midazolam infusions or barbiturate coma. Clobazam's favorable oral and enteral bioavailability theoretically positions it as a viable bridging agent after weaning from intravenous midazolam — an approach directly paralleled by the lorazepam weaning strategy described in the available literature. Its active metabolite N-desmethylclobazam also contributes to a prolonged duration of action suitable for maintenance use.

However, the core pathology of FIRES is immune-mediated encephalitis, and GABA-A enhancement provides symptomatic seizure suppression rather than disease modification. The two supporting publications describe BZD class effects (lorazepam) and a non-BZD adjunct (perampanel) — neither evaluates clobazam directly in FIRES. The TxGNN prediction likely reflects network-level similarity between FIRES and other BZD-responsive epilepsy nodes rather than disease-specific evidence, and should be treated as a hypothesis-generating signal only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35770765	2022	Case Series	Epileptic Disorders	Enteral lorazepam used as effective weaning substitute for midazolam-dependent FIRES patients; demonstrates that enteral BZDs can support the transition from IV anaesthetic coma to oral maintenance — indirect class-effect support for clobazam
39958143	2025	Case Report	Cureus	Perampanel reduced barbiturate dependency in a 13-year-old FIRES patient; highlights the unmet clinical need for alternative AEDs in the weaning phase and the broader context of refractory FIRES management

Saudi Arabia Market Information

No authorizations found for Clobazam in Saudi Arabia.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis for clobazam in FIRES is plausible at the class level (benzodiazepines are routinely used for acute FIRES seizure control), but there are zero clinical trials and no publications examining clobazam specifically in this syndrome. The evidence level (L4) reflects indirect preclinical and mechanistic reasoning only. Additionally, clobazam is not marketed in Saudi Arabia, meaning even an exploratory trial would require special regulatory authorization.

To proceed, the following is needed:

Formal documentation of clobazam's mechanism of action (GABA-A pharmacology, receptor subtype selectivity)
Case reports or retrospective series specifically evaluating enteral clobazam during the subacute or chronic phase of FIRES
Comparative data against lorazepam and clonazepam in BZD weaning protocols for FIRES patients
Assessment of tolerance development and neurocognitive effects during prolonged pediatric use
Safety profile review from package insert (FDA/EMA), particularly warnings on sedation, respiratory depression, and paradoxical excitation in pediatric populations
Saudi Arabia special drug import application (special access authorization) if any clinical use is contemplated
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.